We are live on ! Find out more
GDTC icon

CytoMed Therapeutics
GDTC

3 hedge funds and large institutions have $16.3K invested in CytoMed Therapeutics in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.31% less ownership

Funds ownership: 0.45% → 0.14% (-0.31%)

40% less funds holding

Funds holding: 5 → 3 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

77% less capital inflows, than outflows

Capital inflows: $16.1K | Capital outflows: $69.3K

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XTX Topco
XTX Topco
Cayman Islands
+$10.7K
2
UBS Group
UBS Group
Switzerland
+$5.39K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$39.7K
2
Two Sigma Securities
Two Sigma Securities
New York
-$15.8K
3
StoneX Group
StoneX Group
New York
-$13.8K

GDTC Hedge Fund Activity: Q1 2026 in Review

3 of the 8,217 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q1 2026, worth a combined $16.3K — down 77% from $70.8K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of GDTC and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was XTX Topco, opening a new position worth an estimated $10.7K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $39.7K sold.

  • 3 institutional investors held CytoMed Therapeutics (GDTC) as of Q1 2026, down from 5 in Q4 2025.
  • Funds reported $16.3K of CytoMed Therapeutics stock for Q1 2026, down 77% quarter-over-quarter.
  • 1 fund opened new CytoMed Therapeutics positions in Q1 2026 and 3 closed out, a net change of -2 holders.
  • The largest CytoMed Therapeutics buyer in Q1 2026 was XTX Topco, an estimated $10.7K added.
  • The largest CytoMed Therapeutics seller in Q1 2026 was Susquehanna International Group, an estimated $39.7K sold.

Based on aggregated 13F filings for Q1 2026.